Aflac remains a Buy despite a Q1 earnings miss, supported by organic policy growth, proven dividend increases, and robust balance sheet strength. Growth catalysts include new policy sales, expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results